This topic contains 1 reply, has 1 voice, and was last updated by Gilbert 1 year, 2 months ago.
February 27, 2018 at 11:25 am #790
MN Heenaye- Mamode Khan, NJS. Fauzee, H Neetoo, N Mamode Khan, Z Toorabally, S Uppiah, SS Manraj
Full Title: An interactive tool for Mauritian women to estimate the risk of developing breast cancer in the future.
The Republic of Mauritius being a developing country, cancer is the second leading cause of mortality and morbidity after diabetes, cardiovascular diseases and their complications, accounting for about 7.5%, of overall causes of death among the population. Since the beginning of year 2016, at least 554 new cases of breast cancer and 186 cases of mortality have been registered by the Mauritius National Cancer Registry based at Victoria Hospital. With an Age Standardized Rate (ASR (W)) of 62.76/ 100,000, we are the highest in Africa. According to Professor Clément Adebamowo, consultant with the World Health Organization (WHO), this alarming rate may be related largely to demographic and genetic factors although behavioural factors are also being increasingly considered to be important risk factors. Unfortunately, till date, most epidemiological research on breast cancer has always been done in the European, Asian and African continents. However, given the genetic polymorphisms of different populations, similar epidemiological studies are clearly warranted for Mauritius. Given these alarming figures, there is a strong need to have a thorough comprehensive knowledge on the epidemiological risk factors that may contribute to female breast cancer and to assess their strength in view of determining the possible treatment and preventive methods. Early diagnosis and targeted therapy administered to patients can help to reduce mortality rate and improve the quality of life for cancer patients.
• To develop intelligent tools and use predictive analytics to improve cancer patients outcomes, depending on epidemiological and behavioural risk factors.
• Immunohistochemistry testing routinely for all breast cancer patients and their molecular subtyping for targeted therapy (cost effectiveness is important).
• Genetic testing for co-sanguinous relatives having breast cancer.
• Palliative care for all end-stage breast cancer patients.
This will lead to a reduction of the national economic burden associated with screening, diagnosis and treatment of female breast cancer and an improvement in the quality of life of Mauritian women and families at risk of suffering from it.March 2, 2018 at 3:19 pm #825
Isn’t it high time to team up for attenuating breast and other cancers here?